Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study

Human Gene Therapy

Volumn 12, Issue 6, 2001, Pages 671-684

  Won Ki Kang, ^a   Park, C ^a   Hyunah Lee Yoon, ^a   Won Seog Kim, ^a   Yoon, S S ^a   Lee, M H ^a   Park, K ^a   Kim, K ^a   Hyun Sik Jeong, ^a   Kim, J A ^a,b   Nam, S J ^a   Yang, J H ^a   Son, Y I ^a   Baek, C H ^a   Han, J ^a   Ree, H J ^a   Eil Soo Lee, ^a   Sun Hee Kim, ^a   Kim, D W ^a   Yong Chan Ahn, ^a   Seung Jae Huh, ^a   Yeon Hyeon Choe, ^a   Lee, J H ^a   Park, M H ^a   Kong, G S ^a   Park, E Y ^a   Kang, Y K ^c   Bang, Y J ^d   Paik, N S ^e   Soon Nam Lee, ^f   Kim, S H ^g   Kim, S ^g   Robbins, P D ^h   Tahara, H ^h   Lotze, M T ^h   Park, C H ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

^f Ewha Womans University   (South Korea)

^g Seoul National University   (South Korea)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; KANAMYCIN KINASE; PROTEIN P35; PROTEIN P40; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FIBROBLAST; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOMODULATION; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VOLUME;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FIBROBLASTS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-12; KILLER CELLS, NATURAL; MALE; MELANOMA; MIDDLE AGED; RETROVIRIDAE; SKIN NEOPLASMS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035831628     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401300057388     Document Type: Article

References (38)

1. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
2. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12
3. B7-1 and interleukin 12 synergistically induce effective antitumor immunity
4. Both tumor necrosis factor and nitric oxide participate in lysis of simian virus 40-transformed cells by activated macrophages
5. Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells
6. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor
7. After initial setback, IL-12 regaining popularity
8. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
9. Exogenous IL-12 induces in vivo IL-10 production, followed by downregulation of IL-12 ac-tivites
10. A Mus dunni cell line that lacks sequences closely related to endogenous murine luekemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses
11. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
12. Cancer trial of interleukin-12 halted
13. Reporting results of cancer treatment
14. Murine interleukin-12 prevents the development of cancer cachexia in a murine model
15. Recombinant IL-12 administration induced tumor regression in association with IFN-gamma production
16. + NK cells
17. The inhibition of neoplastic cell proliferation with human natural tumor necrosis factor
18. The antitumor function of tumor necrosis factor (TNF). II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma
19. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: Role of tumor necrosis factor and glucocorticoids
20. Production of IL-12 from gene modified human dermal fibroblasts (a preclinical study for IL-12 cancer gene therapy)
21. Phase I study of intratumoral application of recombinant human tumor necrois factor
22. Antitumor activities of IL-12 and mechanisms of action
23. Design and analysis of clinical trial
24. Modulation of the development of humoral immunity by topically applied acetone, ethanol, and 12-O-tetradecanoylphorbol-13-acetate
25. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells
26. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo
27. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retro-viral vector
28. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts
29. Antitumor effect in patients with melanoma, head and neck, and breast cancer in a phase I/II clinical trial of interleukin-12 (IL-12) gene therapy
30. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target
31. The two faces of interleukin 12: A proinflammatory cytokine and a key immunoregulatory molecule produced by antigen-presenting cells
32. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells
33. Interleukin 12: A key modulator of immune function
34. + T cells
35. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12
36. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12
37. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts
38. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-gamma production of anti-tumor T cells